Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT ...Middle East

PR Newswire - News
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other studies, etripamil was well tolerated by patients - - Data to be featured during late breaking session at Heart Rhythm 2022 - MONTREAL and CHARLOTTE, N.C., April 30,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT )

Also on site :